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88 Levoﬂoxacin pharmacokinetics (PK) after administration of MP-376
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S.M. Bhavnani2, J.S. Loutit3, P.G. Ambrose2, M.N. Dudley3. 1Children’s Mercy
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United States; 3Mpex Pharmaceuticals, San Diego, CA, United States; 4Nemours
Children’s Clinic, Orlando, FL, United States
Introduction: MP-376 is a proprietary formulation of levoﬂoxacin (LVX) for
aerosol administration. We characterized LVX serum and sputum exposures in
children with CF receiving MP-376.
Methods: Medically stable patients with CF aged 6−16 years (FEV1 range 37
to 127% of predicted) were enrolled. Patients received single daily doses or MP-
376 of either 180 (n = 7) or 240mg (n = 20) for 14 days via a customized eFlow
nebulizer based on body weight of 22−29 kg and 30 kg, respectively. Repeated
serum and sputum samples were collected for LVX concentration on Days 1 and
14. PK analyses were conducted using non-compartmental methods.
Results: 25 patients had evaluable data to estimate serum PK parameters on at
least one occasion (22 from both days, 3 from Day 1 only). Mean serum AUC
(CV%) was 8.1 (77.1) and 9.8 (55.7)mg*h/L and mean serum Cmax (CV%) was
1.2 (81.2) and 1.5 (62.8)mg/L for 180 and 240mg doses, respectively. Sputum
Cmax was highly variable and the mean (CV%) for both doses combined was 3120
(188)mg/L on Day 1 (n = 13). There was no apparent association between total
body weight and/or age with LVX serum or sputum exposure.
Conclusions: Serum and sputum LVX levels in pediatric CF patients are comparable
to those observed following aerosol MP-376 in adult CF patients. Based on these
data, children 6 years of age and older and weighing at least 30 kg should receive
the same dose as adult CF patients.
89 Superior effects of RV568, a narrow spectrum kinase inhibitor, on
RSV infection in primary bronchial epithelial cells obtained from
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Objectives: Respiratory syncytial virus (RSV) is a leading cause of serious lower
respiratory infections in patients with respiratory disorders such as cystic ﬁbrosis;
however, there are no viable treatments available. The aim of this study is to evaluate
the effects of RV568, a narrow spectrum kinase inhibitor (NSKI), on RSV infection
in human bronchial epithelial cells from healthy volunteers (NHBEC) and patients
with cystic ﬁbrosis (CF-BEC) and Hep2 cells.
Methods: RSV A2 strain was infected to Hep2, NHBEC and CF-BEC at 0.001MOI
for 1 hr and then non-infected virus was washed out. The plates were further
incubated for 4 days and RSV infection was assessed by ELISA targeting RSV
fusion (F) protein.
Results: RSV infected all three cell types but CF-and NHBEC showed greater
infection than Hep2 cells. RV568, ﬂuticasone propionate (FP), a corticosteroid,
and Ribavirin were added 2 hrs before and 1 hr after infection. FP (0.04 ug/ml or
0.2 ug/ml) did not inhibit RSV infection in any cell type. Ribavirin (10 ug/ml)
inhibited RSV-F protein expression by 93% in Hep2 cells, but the maximum
inhibitory effects were reduced in primary cells (78% in HBEC, 53% in CF-BEC).
In contrast, although RV568 inhibited RSV load by only 24% in Hep2, it showed
superior effects in NHBEC (IC50 values of 41 nM and E-max of 51%), and the
efﬁcacy was improved in CF-BEC (IC50 value of 69 nM and E-max of 84%). At
the concentrations used, no effects on cell viability were detected.
Conclusions: RV568 is a novel compound which inhibits RSV replication by
targeting host cell signaling, suggesting that RV568 could be an important new
therapy for cystic ﬁbrosis especially RSV-induced exacerbation.
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Objectives: Respiratory syncytial virus (RSV) is a leading cause of serious lower
respiratory infections in patients with respiratory disorders such as cystic ﬁbrosis;
however, there are no viable treatments available. The aim of this study is to
evaluate the effects of RV1088, a narrow spectrum kinase inhibitors (NSKI), on
RSV infection in human bronchial epithelial cells from healthy volunteers (NHBEC)
and patients with cystic ﬁbrosis (CF-BEC) and Hep2 cells.
Methods: RSV A2 strain was infected to Hep2, NHBEC and CF-BEC at 0.001MOI
for 1 hr and then non-infected virus was washed out. The plates were further
incubated for 4 days and RSV infection was assessed by ELISA targeting RSV
fusion (F) protein.
Results: RSV infected all three cell types but CF-and NHBEC showed greater
infection than Hep2 cells. RV1088, ﬂuticasone propionate (FP), a corticosteroid,
and Ribavirin were added 2hrs before and 1 hr after infection. FP (0.04 ug/ml or
0.2 ug/ml) did not inhibit RSV infection in any cell type. Ribavirin (10 ug/ml)
inhibited RSV-F protein expression by 93% in Hep2 cells, but the maximum
inhibitory effects were reduced in primary cells (78% in HBEC, 53% in CF-BEC).
In contrast, although RV1088 inhibited RSV load by only 58% at maximum in
Hep2, RV1088 showed superior effects in both NHBEC (IC50 value of 22 nM and
E-max of 87%) and in CF-BEC (IC50 value of 58 nM and E-max of 78%). At the
concentrations used, no effects on cell viability were detected.
Conclusion: RV1088 is a novel compound which inhibits RSV replication by
targeting host cell signaling, suggesting that RV1088 could be an important new
therapy for cystic ﬁbrosis especially RSV-induced exacerbation.
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Objective: In addition to its antibiotic activity, Azithromycin (AZM) has anti-
inﬂammatory, immunomodulatory and mucus regulating effects. Since oral bioavail-
ability is only about 37%, inhalation can provide high local doses in the airways
as the target site to treat CF and bronchiectasis (BE). Topical use of aerosolized
azithromycin may increase mucociliary clearance, decrease mucus hypersecretion
and reduce IL8, neutrophils, rhinovirus replication, pro-inﬂammatory proteins, nasal
polyps, and protect ciliated epithelium against oxidative damage. Hence, based on
such literature data local effects of AZM may improve therapeutic efﬁcacy over oral
or i.v. application reducing at the same adverse side effects and resistance formation
as known from other inhaled antibiotics.
Results: Drug delivery efﬁciency of a novel taste masked AZM solution
(100mg/mL) utilizing a customised eFlow electronic nebuliser was assessed by
breath simulation tests carried out in triplicate, each. In-vitro delivered doses
(DDs) of ~75% and respirable dose (RD) of ~50% suggest that a lung deposition
of about 40% can be expected. Inhalation tests conﬁrmed good tolerability and
acceptable taste.
Conclusion: Targeted aerosolized AZM therapy by nebulisation via eFlow tech-
nology platform devices may be more advantageous and effective compared to
oral application. Hence, the proposed targeted delivery concept of a novel AZM
inhalation formulation may open new perspectives for the treatment of CF and BE
as well as severe neutrophilic asthma, COPD and mycobacterium avium complex
induced infections. Thus, clinical studies are warranted to evaluate the therapeutic
value of inhaled Azithromycin.
